Clinical Trial Update: The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of PEG-rhG-CSF to prevent chemotherapy-induced neutropenia in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: wang shusen | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN